Related Experiment Video
Updated: Jun 6, 2026
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
Published on: July 18, 2016
Searching for potential biomarkers of cisplatin resistance in human ovarian cancer using a label-free LC/MS-based
Dawn P G Fitzpatrick1, Jin-Sam You, Kerry G Bemis
1Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA.
Abstract:
Platinum-based chemotherapy, such as cisplatin, is the primary treatment for ovarian cancer. However, drug resistance has become a major impediment to the successful treatment of ovarian cancer. To date, the molecular mechanisms of resistance to platinum-based chemotherapy remain unclear. In this study, we applied an LC/MS-based protein quantification method to examine the global protein expression of two pairs of ovarian cancer cell lines, A2780/A2780-CP (cisplatin-sensitive/cisplatin-resistant) and 2008/2008-C13*5.25 (cisplatin-sensitive/cisplatin-resistant). We identified and quantified over 2000 proteins from these cell lines and 760 proteins showed significant expression changes with a false discovery rate of less than 5% between paired groups. Based on the results we obtained, we suggest several potential pathways that may be involved in cisplatin resistance in human ovarian cancer. This study provides not only a new proteomic platform for large-scale quantitative protein analysis, but also important information for discovery of potential biomarkers of cisplatin resistance in ovarian cancer. Furthermore, these results may be clinically relevant for diagnostics, prognostics, and therapeutic improvement for ovarian cancer treatment.
Insights
Researchers investigated cisplatin resistance in ovarian cancer using proteomic analysis. They identified significant protein expression changes, revealing potential pathways and biomarkers for improved diagnostics and therapeutics.
Area of Science:
- Oncology
- Proteomics
- Molecular Biology
Background:
- Platinum-based chemotherapy, including cisplatin, is a cornerstone treatment for ovarian cancer.
- Acquired drug resistance to chemotherapy significantly hinders treatment efficacy and patient outcomes.
- The precise molecular mechanisms underlying cisplatin resistance in ovarian cancer are not fully understood.
Purpose of the Study:
- To investigate global protein expression differences between cisplatin-sensitive and cisplatin-resistant ovarian cancer cell lines.
- To identify potential molecular pathways and protein biomarkers associated with cisplatin resistance.
- To establish a proteomic platform for large-scale quantitative protein analysis in ovarian cancer research.
Main Methods:
- Utilized liquid chromatography-tandem mass spectrometry (LC/MS) for quantitative proteomic analysis.
- Compared protein expression profiles in two paired sets of ovarian cancer cell lines (A2780/A2780-CP and 2008/2008-C13*5.25).
- Analyzed over 2000 proteins, identifying 760 with statistically significant expression changes (FDR < 5%).
Main Results:
- Identified substantial differences in global protein expression between sensitive and resistant ovarian cancer cell lines.
- Over 760 proteins exhibited significant expression changes, suggesting their involvement in cisplatin resistance.
- Several potential molecular pathways implicated in cisplatin resistance were proposed based on the proteomic data.
Conclusions:
- This proteomic study provides critical insights into the molecular mechanisms of cisplatin resistance in ovarian cancer.
- The identified protein expression changes offer potential biomarkers for diagnosing, prognosing, and treating ovarian cancer.
- The findings may contribute to the development of more effective therapeutic strategies and improved patient outcomes.
